# Tempus AI, Inc.: financial statements, quarterly TEM · Nasdaq · CIK 1717115 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tem.md) · [Financials](/companies/tem/financials.md) · [Filings](/companies/tem/filings.md) · [Insiders](/companies/tem/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tem/financials.md?period=annual). ## Income statement | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [136](/filings/0000950170-24-120677.md) | [148 d](/filings/0001193125-26-066961.md) | [146](/filings/0000950170-25-064447.md) | [166](/filings/0000950170-25-105449.md) | [181](/filings/0001193125-25-264652.md) | [201 d](/filings/0001193125-26-066961.md) | [256](/filings/0001193125-26-206356.md) | [315](/filings/0001193125-26-326090.md) | [334](/filings/0001193125-25-264652.md) | [367 d](/filings/0001193125-26-066961.md) | [348](/filings/0001193125-26-206356.md) | [382](/filings/0001193125-26-326090.md) | | Research and development | $m | [23.2](/filings/0000950170-24-120677.md) | [24.1 d](/filings/0001193125-26-066961.md) | [24.3](/filings/0000950170-25-064447.md) | [68.0](/filings/0000950170-25-105449.md) | [27.3](/filings/0001193125-25-264652.md) | [29.6 d](/filings/0001193125-26-066961.md) | [35.9](/filings/0001193125-26-206356.md) | [41.6](/filings/0001193125-26-326090.md) | [45.0](/filings/0001193125-25-264652.md) | [50.5 d](/filings/0001193125-26-066961.md) | [48.2](/filings/0001193125-26-206356.md) | [52.6](/filings/0001193125-26-326090.md) | | Selling, general and administrative | $m | [71.4](/filings/0000950170-24-120677.md) | [85.1 d](/filings/0001193125-26-066961.md) | [79.6](/filings/0000950170-25-064447.md) | [463](/filings/0000950170-25-105449.md) | [101](/filings/0001193125-25-264652.md) | [111 d](/filings/0001193125-26-066961.md) | [155](/filings/0001193125-26-206356.md) | [181](/filings/0001193125-26-326090.md) | [188](/filings/0001193125-25-264652.md) | [209 d](/filings/0001193125-26-066961.md) | [213](/filings/0001193125-26-206356.md) | [226](/filings/0001193125-26-326090.md) | | Operating income | $m | [(44.8)](/filings/0000950170-24-120677.md) | [(52.3) d](/filings/0001193125-26-066961.md) | [(53.3)](/filings/0000950170-25-064447.md) | [(533)](/filings/0000950170-25-105449.md) | [(53.6)](/filings/0001193125-25-264652.md) | [(50.7) d](/filings/0001193125-26-066961.md) | [(68.7)](/filings/0001193125-26-206356.md) | [(61.8)](/filings/0001193125-26-326090.md) | [(61.0)](/filings/0001193125-25-264652.md) | [(61.4) d](/filings/0001193125-26-066961.md) | [(84.7)](/filings/0001193125-26-206356.md) | [(75.9)](/filings/0001193125-26-326090.md) | | Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-064447.md) | [0.1](/filings/0000950170-25-105449.md) | [0.0](/filings/0001193125-25-264652.md) | [0.1 d](/filings/0001193125-26-066961.md) | [(46.2)](/filings/0001193125-26-206356.md) | [0.2](/filings/0001193125-26-326090.md) | [0.3](/filings/0001193125-25-264652.md) | [(6.0) d](/filings/0001193125-26-066961.md) | [(0.1)](/filings/0001193125-26-206356.md) | [0.3](/filings/0001193125-26-326090.md) | | Net income | $m | [(53.4)](/filings/0000950170-24-120677.md) | [(50.5) d](/filings/0001193125-26-066961.md) | [(64.7)](/filings/0000950170-25-064447.md) | [(552)](/filings/0000950170-25-105449.md) | [(75.8)](/filings/0001193125-25-264652.md) | [(13.0) d](/filings/0001193125-26-066961.md) | [(68.0)](/filings/0001193125-26-206356.md) | [(42.8)](/filings/0001193125-26-326090.md) | [(80.0)](/filings/0001193125-25-264652.md) | [(54.2) d](/filings/0001193125-26-066961.md) | [(126)](/filings/0001193125-26-206356.md) | [5.6](/filings/0001193125-26-326090.md) | | Diluted EPS | $ per share | [(1.03)](/filings/0000950170-24-120677.md) | not reported | [(1.47)](/filings/0000950170-25-064447.md) | [(6.86)](/filings/0000950170-25-105449.md) | [(0.46)](/filings/0001193125-25-264652.md) | not reported | [(0.40)](/filings/0001193125-26-206356.md) | [(0.25)](/filings/0001193125-26-326090.md) | [(0.46)](/filings/0001193125-25-264652.md) | not reported | [(0.71)](/filings/0001193125-26-206356.md) | [0.03](/filings/0001193125-26-326090.md) | | Basic EPS | $ per share | [(1.03)](/filings/0000950170-24-120677.md) | not reported | [(1.47)](/filings/0000950170-25-064447.md) | [(6.86)](/filings/0000950170-25-105449.md) | [(0.46)](/filings/0001193125-25-264652.md) | not reported | [(0.40)](/filings/0001193125-26-206356.md) | [(0.25)](/filings/0001193125-26-326090.md) | [(0.46)](/filings/0001193125-25-264652.md) | not reported | [(0.70)](/filings/0001193125-26-206356.md) | [0.03](/filings/0001193125-26-326090.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [133](/filings/0000950170-24-120677.md) | [166](/filings/0001193125-26-066961.md) | [79.9](/filings/0000950170-25-064447.md) | [479](/filings/0000950170-25-105449.md) | [388](/filings/0001193125-25-264652.md) | [341](/filings/0001193125-26-066961.md) | [152](/filings/0001193125-26-206356.md) | [186](/filings/0001193125-26-326090.md) | [656](/filings/0001193125-25-264652.md) | [605](/filings/0001193125-26-326090.md) | [521](/filings/0001193125-26-206356.md) | [600](/filings/0001193125-26-326090.md) | | Current assets | $m | not reported | [350](/filings/0000950170-25-025603.md) | not reported | [671](/filings/0001193125-24-194869.md) | [679](/filings/0000950170-24-120677.md) | [668](/filings/0001193125-26-066961.md) | [574](/filings/0000950170-25-064447.md) | [644](/filings/0000950170-25-105449.md) | [1,147](/filings/0001193125-25-264652.md) | [1,167](/filings/0001193125-26-326090.md) | [1,054](/filings/0001193125-26-206356.md) | [1,291](/filings/0001193125-26-326090.md) | | Total assets | $m | not reported | [564](/filings/0000950170-25-025603.md) | not reported | [865](/filings/0001193125-24-194869.md) | [972](/filings/0000950170-24-120677.md) | [926](/filings/0001193125-26-066961.md) | [1,543](/filings/0000950170-25-064447.md) | [1,625](/filings/0000950170-25-105449.md) | [2,281](/filings/0001193125-25-264652.md) | [2,275](/filings/0001193125-26-326090.md) | [2,135](/filings/0001193125-26-206356.md) | [2,366](/filings/0001193125-26-326090.md) | | Current liabilities | $m | not reported | [233](/filings/0000950170-25-025603.md) | not reported | [182](/filings/0001193125-24-194869.md) | [253](/filings/0000950170-24-120677.md) | [291](/filings/0001193125-26-066961.md) | [336](/filings/0000950170-25-064447.md) | [418](/filings/0000950170-25-105449.md) | [350](/filings/0001193125-25-264652.md) | [372](/filings/0001193125-26-326090.md) | [318](/filings/0001193125-26-206356.md) | [391](/filings/0001193125-26-326090.md) | | Total liabilities | $m | not reported | [841](/filings/0000950170-25-025603.md) | not reported | [766](/filings/0001193125-24-194869.md) | [918](/filings/0000950170-24-120677.md) | [870](/filings/0001193125-26-066961.md) | [1,217](/filings/0000950170-25-064447.md) | [1,316](/filings/0000950170-25-105449.md) | [1,774](/filings/0001193125-25-264652.md) | [1,784](/filings/0001193125-26-326090.md) | [1,719](/filings/0001193125-26-206356.md) | [1,921](/filings/0001193125-26-326090.md) | | Shareholders' equity | $m | [(1,325)](/filings/0000950170-24-120677.md) | [(1,382)](/filings/0001193125-26-066961.md) | [(1,474)](/filings/0000950170-25-105449.md) | [98.3](/filings/0001193125-25-264652.md) | [53.7](/filings/0001193125-25-264652.md) | [56.3](/filings/0001193125-26-326090.md) | [326](/filings/0001193125-26-326090.md) | [310](/filings/0001193125-26-326090.md) | [508](/filings/0001193125-25-264652.md) | [491](/filings/0001193125-26-326090.md) | [416](/filings/0001193125-26-326090.md) | [445](/filings/0001193125-26-326090.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(53.0) d](/filings/0000950170-24-120677.md) | [(40.3) d](/filings/0001193125-26-066961.md) | [(101)](/filings/0000950170-25-064447.md) | [(97.1) d](/filings/0000950170-25-105449.md) | [48.7 d](/filings/0001193125-25-264652.md) | [(39.3) d](/filings/0001193125-26-066961.md) | [(106)](/filings/0001193125-26-206356.md) | [44.2 d](/filings/0001193125-26-326090.md) | [(120) d](/filings/0001193125-25-264652.md) | [(36.8) d](/filings/0001193125-26-066961.md) | [(73.3)](/filings/0001193125-26-206356.md) | [(7.5) d](/filings/0001193125-26-326090.md) | | Capital expenditure | $m | [16.0 d](/filings/0000950170-24-120677.md) | [2.7 d](/filings/0001193125-26-066961.md) | [6.1](/filings/0000950170-25-064447.md) | [8.0 d](/filings/0000950170-25-105449.md) | [0.0 d](/filings/0001193125-25-264652.md) | [8.0 d](/filings/0001193125-26-066961.md) | [2.1](/filings/0001193125-26-206356.md) | [7.5 d](/filings/0001193125-26-326090.md) | [6.7 d](/filings/0001193125-25-264652.md) | [4.8 d](/filings/0001193125-26-066961.md) | [8.2](/filings/0001193125-26-206356.md) | [6.1 d](/filings/0001193125-26-326090.md) | | Dividends paid | $m | [0.0 d](/filings/0000950170-24-120677.md) | [0.0 d](/filings/0001193125-26-066961.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-264652.md) | [0.0 d](/filings/0001193125-26-066961.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-264652.md) | [0.0 d](/filings/0001193125-26-066961.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends ## Shares | Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | thousands of shares | [63.3](/filings/0001193125-24-194869.md) | [63.3](/filings/0000950170-24-120677.md) | [63.4](/filings/0000950170-25-064447.md) | [82.3](/filings/0000950170-25-105449.md) | [166](/filings/0001193125-25-264652.md) | [171](/filings/0001193125-26-206356.md) | [173](/filings/0001193125-26-326090.md) | [175](/filings/0001193125-25-264652.md) | [179](/filings/0001193125-26-206356.md) | [182](/filings/0001193125-26-326090.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.